Exponent authors James Bus and Steave Su, along with co-authors, have conducted a cancer risk assessment for styrene, addressing concerns about its potential to cause lung cancer in occupational settings. Their publication, 'Styrene lung cancer risk assessment,' performs benchmark dose (BMD) modeling of mouse lung tumor dose response data.
The study derived occupational and general population inhalation reference concentrations (RfCs) designed to be protective of lung cancer concerns. This RfC-based approach was implemented as a conservative risk assessment alternative to comprehensive mode of action analyses.
Using a weight-of-evidence examination, the authors found that styrene and its primary metabolite styrene oxide (SO) appear unlikely to be genotoxic in vivo. The integrated data analyses conclude that, even if mouse lung tumors are conservatively considered human relevant, 'typical occupational and general population exposures are a low-priority concern for human lung risk.'
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.